$GH
Guardant Health, Inc.

2023 Q4 Form 10-Q Financial Statement

#000157628023000187 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $155.1M $143.0M
YoY Change 22.19% 21.83%
Cost Of Revenue $62.52M $57.60M
YoY Change 32.67% 42.24%
Gross Profit $92.54M $85.40M
YoY Change 16.0% 11.04%
Gross Profit Margin 59.68% 59.71%
Selling, General & Admin $116.8M $105.1M
YoY Change -2.11% -13.48%
% of Gross Profit 126.21% 123.08%
Research & Development $89.86M $93.85M
YoY Change -15.69% -6.16%
% of Gross Profit 97.1% 109.9%
Depreciation & Amortization $10.87M $10.30M
YoY Change 6.9% 13.19%
% of Gross Profit 11.75% 12.06%
Operating Expenses $290.0M $199.0M
YoY Change 28.4% -10.18%
Operating Profit -$197.5M -$113.5M
YoY Change 35.17% -21.48%
Interest Expense -$151.0M $644.0K
YoY Change -2285.88% 0.0%
% of Operating Profit
Other Income/Expense, Net $167.9M $16.89M
YoY Change -141178.99% -191.82%
Pretax Income -$187.6M -$85.61M
YoY Change 34.63% -47.11%
Income Tax -$541.0K $490.0K
% Of Pretax Income
Net Earnings -$187.0M -$86.10M
YoY Change 33.67% -46.85%
Net Earnings / Revenue -120.63% -60.2%
Basic Earnings Per Share -$0.73
Diluted Earnings Per Share -$1.58 -$0.73
COMMON SHARES
Basic Shares Outstanding 118.0M shares 117.7M shares
Diluted Shares Outstanding 117.7M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.169B $1.155B
YoY Change 15.57% 20.54%
Cash & Equivalents $1.134B $457.3M
Short-Term Investments $35.10M $697.5M
Other Short-Term Assets $27.74M $26.20M
YoY Change -11.96% 11.18%
Inventory $61.95M $77.04M
Prepaid Expenses
Receivables $88.78M $88.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.347B $1.347B
YoY Change 13.05% 19.1%
LONG-TERM ASSETS
Property, Plant & Equipment $145.1M $147.7M
YoY Change -13.59% -12.1%
Goodwill $3.290M $3.290M
YoY Change 0.0% 0.0%
Intangibles $8.979M $9.670M
YoY Change -23.43% -22.12%
Long-Term Investments
YoY Change
Other Assets $124.3M $128.0M
YoY Change 102.32% 147.52%
Total Long-Term Assets $439.3M $450.3M
YoY Change 5.0% -21.12%
TOTAL ASSETS
Total Short-Term Assets $1.347B $1.347B
Total Long-Term Assets $439.3M $450.3M
Total Assets $1.786B $1.797B
YoY Change 10.96% 5.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $51.74M $77.83M
YoY Change -24.92% 90.24%
Accrued Expenses $188.0M $205.3M
YoY Change 75.81% 223.93%
Deferred Revenue $17.97M $21.49M
YoY Change 3.23% 60.06%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $205.9M $226.8M
YoY Change 6.57% 29.48%
LONG-TERM LIABILITIES
Long-Term Debt $1.140B $1.139B
YoY Change 0.23% 0.22%
Other Long-Term Liabilities $96.01M $10.18M
YoY Change 945.93% 45.71%
Total Long-Term Liabilities $96.01M $10.18M
YoY Change 945.93% 45.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $205.9M $226.8M
Total Long-Term Liabilities $96.01M $10.18M
Total Liabilities $1.628B $1.569B
YoY Change 5.03% 2.21%
SHAREHOLDERS EQUITY
Retained Earnings -$2.142B -$1.955B
YoY Change 28.84% 28.4%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $158.7M $228.3M
YoY Change
Total Liabilities & Shareholders Equity $1.786B $1.797B
YoY Change 10.96% 5.61%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$187.0M -$86.10M
YoY Change 33.67% -46.85%
Depreciation, Depletion And Amortization $10.87M $10.30M
YoY Change 6.9% 13.19%
Cash From Operating Activities -$78.73M -$77.79M
YoY Change -13.25% -0.47%
INVESTING ACTIVITIES
Capital Expenditures $4.076M $2.370M
YoY Change -59.24% -110.91%
Acquisitions
YoY Change
Other Investing Activities $667.5M $263.1M
YoY Change 727.91% 317.59%
Cash From Investing Activities $663.5M $260.7M
YoY Change 839.37% 531.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.57M 3.810M
YoY Change 3807.03% -119.73%
NET CHANGE
Cash From Operating Activities -78.73M -77.79M
Cash From Investing Activities 663.5M 260.7M
Cash From Financing Activities 90.57M 3.810M
Net Change In Cash 675.3M 186.7M
YoY Change -3892.91% -432.25%
FREE CASH FLOW
Cash From Operating Activities -$78.73M -$77.79M
Capital Expenditures $4.076M $2.370M
Free Cash Flow -$82.80M -$80.16M
YoY Change -17.82% 42.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102619383 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102619383 shares
CY2023Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1000 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2188797000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1742114000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5680000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19522000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1954819000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1662413000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
228299000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
60180000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1797231000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1609985000 usd
CY2023Q3 gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
133423000 usd
CY2022Q3 gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
102054000 usd
gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
372060000 usd
gh Revenue From Precision Oncology Testing
RevenueFromPrecisionOncologyTesting
278252000 usd
CY2023Q3 gh Revenue From Development Services
RevenueFromDevelopmentServices
9607000 usd
CY2022Q3 gh Revenue From Development Services
RevenueFromDevelopmentServices
15350000 usd
us-gaap Revenues
Revenues
408894000 usd
us-gaap Revenues
Revenues
322647000 usd
CY2023Q3 gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
53648000 usd
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
457339000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141647000 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
205266000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
175817000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21485000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
17403000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
226751000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
193220000 usd
CY2023Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1139322000 usd
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1137391000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
192677000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
210015000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10182000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9179000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1568932000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1549805000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
117849155 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
117849155 shares
CY2022Q3 gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
39434000 usd
gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
148111000 usd
gh Costs Of Precision Oncology Testing
CostsOfPrecisionOncologyTesting
104493000 usd
CY2023Q3 gh Cost Of Development Services
CostOfDevelopmentServices
3966000 usd
CY2022Q3 gh Cost Of Development Services
CostOfDevelopmentServices
1062000 usd
gh Cost Of Development Services
CostOfDevelopmentServices
16424000 usd
gh Cost Of Development Services
CostOfDevelopmentServices
4711000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93851000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100017000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
277338000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
267229000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
68934000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
80370000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
216100000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
218405000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36174000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41121000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
118135000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
126068000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
256573000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
262004000 usd
us-gaap Costs And Expenses
CostsAndExpenses
776108000 usd
us-gaap Costs And Expenses
CostsAndExpenses
720906000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-113543000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-144600000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-367214000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-398259000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
11690000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1754000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
21477000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3919000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
644000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
644000 usd
us-gaap Interest Expense
InterestExpense
1933000 usd
us-gaap Interest Expense
InterestExpense
1933000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16885000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18389000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56490000 usd
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
CY2022Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117736000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117736000 shares
CY2022Q3 gh Adjustments To Additional Paid In Capital Tender Offer Issued
AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued
4403000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2591000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-161994000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
166745000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
60180000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21131000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381369000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
290000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6697000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
8112000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66439000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
13842000 usd
us-gaap Net Income Loss
NetIncomeLoss
-292406000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
645005000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2504000 usd
gh Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
8000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5742000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
6519000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70982000 usd
gh Adjustments To Additional Paid In Capital Tender Offer Issued
AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued
14235000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22088000 usd
us-gaap Net Income Loss
NetIncomeLoss
-514654000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
166745000 usd
us-gaap Net Income Loss
NetIncomeLoss
-292406000 usd
us-gaap Net Income Loss
NetIncomeLoss
-514654000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32013000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25793000 usd
gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
22146000 usd
gh Non Cash Operating Lease Costs
NonCashOperatingLeaseCosts
21394000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
230000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4195000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
66439000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
70982000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1931000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1926000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
10913000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3366000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
84513000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-13230000 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
29054000 usd
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
5261000 usd
gh Fair Value Adjustments Of Noncontrolling Interest Liability
FairValueAdjustmentsOfNoncontrollingInterestLiability
0 usd
gh Fair Value Adjustments Of Noncontrolling Interest Liability
FairValueAdjustmentsOfNoncontrollingInterestLiability
-99785000 usd
gh Payments For Joint Venture Acquisition Financing Activities
PaymentsForJointVentureAcquisitionFinancingActivities
0 usd
gh Payments For Joint Venture Acquisition Financing Activities
PaymentsForJointVentureAcquisitionFinancingActivities
177785000 usd
gh Noncash Tender Offer Issued
NoncashTenderOfferIssued
0 usd
gh Noncash Tender Offer Issued
NoncashTenderOfferIssued
-14236000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
5910000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1118000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
386807000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-191411000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1941000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2740000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
315415000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-333676000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
141948000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
492288000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
457363000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158612000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3716000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4073000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1805000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8914000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
457339000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158310000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
24000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
302000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
457363000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158612000 usd
CY2022Q4 gh Number Of Patients
NumberOfPatients
40000 segment
CY2022Q3 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 usd
us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
CY2023Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
8600000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
25000000 usd
gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
22100000 usd
CY2022Q3 gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
5300000 usd
CY2023Q2 gh Equity Security Fvni Impairment Of Purchase Rights
EquitySecurityFVNIImpairmentOfPurchaseRights
7000000 usd
gh Equity Security Fvni Impairment Or Adjustments To Carrying Value
EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3800000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
12700000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7700000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
256051000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
117654000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q3 gh Contractual Receivables Before Allowance For Credit Loss
ContractualReceivablesBeforeAllowanceForCreditLoss
8000000 usd
CY2020Q3 gh Contractual Receivables Term
ContractualReceivablesTerm
P6Y
CY2020Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1000000 usd
CY2021Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1100000 usd
CY2022Q4 gh Proceeds From Contractual Receivable
ProceedsFromContractualReceivable
1100000 usd
gh Contractual Receivables Credit Loss Expense Reversal Noncurrent
ContractualReceivablesCreditLossExpenseReversalNoncurrent
4800000 usd
CY2023Q3 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
1100000 usd
CY2022Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Current
ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent
0 usd
CY2023Q3 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 usd
CY2023Q3 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 usd
CY2022Q4 gh Contractual Receivables After Allowance For Credit Loss Net Current
ContractualReceivablesAfterAllowanceForCreditLossNetCurrent
0 usd
CY2023Q3 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
3700000 usd
CY2022Q4 gh Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent
ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent
4800000 usd
CY2023Q3 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
3700000 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 usd
CY2023Q3 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 usd
CY2022Q4 gh Contractual Receivables After Allowance For Credit Loss Net Noncurrent
ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent
0 usd
CY2022Q3 gh Contractual Receivables Allowance For Credit Loss Period Increase Decrease
ContractualReceivablesAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2023Q3 gh Contractual Receivables Allowance For Credit Loss Period Increase Decrease
ContractualReceivablesAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 usd
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
0 usd
gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 usd
gh Contractual Receivables Credit Loss Reclassification Current
ContractualReceivablesCreditLossReclassificationCurrent
1100000 usd
CY2023Q3 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2022Q3 gh Contractual Receivables Allowance For Credit Loss Current
ContractualReceivablesAllowanceForCreditLossCurrent
1100000 usd
CY2022Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
4800000 usd
CY2021Q4 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
5900000 usd
gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 usd
gh Contractual Receivables Credit Loss Reclassification Noncurrent
ContractualReceivablesCreditLossReclassificationNoncurrent
-1100000 usd
CY2023Q3 gh Contractual Receivables Allowance For Credit Loss Noncurrent
ContractualReceivablesAllowanceForCreditLossNoncurrent
3700000 usd
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
5600000 usd
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
5400000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0 usd
CY2023Q3 gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
500000 usd
CY2022Q3 gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
400000 usd
gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
1600000 usd
gh Post Acquisition Contingent Consideration Expense Benefit
PostAcquisitionContingentConsiderationExpenseBenefit
2700000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
24400000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
21200000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2900000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
265325000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
88131000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147671000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
167920000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
10300000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
9100000 usd
us-gaap Depreciation
Depreciation
29900000 usd
us-gaap Depreciation
Depreciation
23900000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
77828000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
68911000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
62676000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
55788000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26356000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21878000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38406000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29240000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
205266000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
175817000 usd
CY2023Q3 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
1074226000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
31000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1019000 usd
CY2023Q3 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
1073238000 usd
CY2022Q4 gh Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost
DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost
904446000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16779000 usd
CY2022Q4 gh Cash Cash Equivalents And Debt Securities Fair Value
CashCashEquivalentsAndDebtSecuritiesFairValue
887675000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
96885000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
92000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
161618000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
927000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
258503000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1019000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
170975000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2958000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
685754000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
13821000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
856729000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
16779000 usd
CY2023Q3 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Realized Gain Loss
DebtSecuritiesRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18586000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8916000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9670000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
3290000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
3290000 usd
CY2023Q3 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8916000 usd
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
12960000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
18586000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6859000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
11727000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3290000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
3290000 usd
CY2022Q4 gh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
21876000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6859000 usd
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
15017000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2100000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
690000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2219000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1670000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1212000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1107000 usd
CY2023Q3 gh Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
2772000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9670000 usd
CY2020Q4 gh Convertible Debt Hedge Strike Price
ConvertibleDebtHedgeStrikePrice
182.60
CY2020Q4 gh Convertible Debt Hedge Share Price Premium Percentage
ConvertibleDebtHedgeSharePricePremiumPercentage
0.75
CY2020Q4 us-gaap Share Price
SharePrice
104.34
CY2020Q4 gh Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges
90000000 usd
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
7400000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
7200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
22100000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
21400000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y1M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0389
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0393
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8632000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
34158000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
33195000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
28148000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
24479000 usd
CY2023Q3 gh Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
125157000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
253769000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34736000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
219033000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.42
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
us-gaap Dividends Common Stock
DividendsCommonStock
0 usd
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25109231 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16249546 shares
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14375000 shares
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
28.00
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
381400000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21100000 usd
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5438296 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3402574 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
34.34
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39749000 usd
gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
534552 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.55
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40868 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
194927 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
65.89
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
13764260 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3701331 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
33.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43284000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2253535 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
23.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M24D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
42275000 usd
CY2023Q1 gh Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable
3689000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
33.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
22.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.49
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
38900000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21819000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20639000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
66439000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70982000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2022Q3 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-86102000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-86102000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-161994000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-161994000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-292406000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-292406000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-514654000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-514654000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
117736000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117736000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102289000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102289000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109791000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109791000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102065000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102065000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17937000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16617000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17923000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15617000 shares
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Revenues
Revenues
143030000 usd
CY2022Q3 us-gaap Revenues
Revenues
117404000 usd
us-gaap Revenues
Revenues
408894000 usd
us-gaap Revenues
Revenues
322647000 usd

Files In Submission

Name View Source Status
gh-20230930_def.xml Edgar Link unprocessable
gh-20230930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
gh-20230930_lab.xml Edgar Link unprocessable
0001576280-23-000187-index-headers.html Edgar Link pending
0001576280-23-000187-index.html Edgar Link pending
0001576280-23-000187.txt Edgar Link pending
0001576280-23-000187-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gh-09302023x10qxex101.htm Edgar Link pending
gh-09302023x10qxex102.htm Edgar Link pending
gh-09302023x10qxex311.htm Edgar Link pending
gh-09302023x10qxex312.htm Edgar Link pending
gh-09302023x10qxex313.htm Edgar Link pending
gh-09302023x10qxex321.htm Edgar Link pending
gh-09302023x10qxex322.htm Edgar Link pending
gh-09302023x10qxex323.htm Edgar Link pending
gh-20230930.htm Edgar Link pending
gh-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
gh-20230930_pre.xml Edgar Link unprocessable
gh-20230930_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending